PensionDanmark Pensionsforsikringsaktieselskab Acquires 2,700 Shares of IQVIA Holdings Inc. $IQV

PensionDanmark Pensionsforsikringsaktieselskab boosted its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV) by 9.8% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 30,122 shares of the medical research company’s stock after buying an additional 2,700 shares during the quarter. PensionDanmark Pensionsforsikringsaktieselskab’s holdings in IQVIA were worth $5,820,000 at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. Financial Freedom LLC acquired a new position in shares of IQVIA during the 1st quarter worth approximately $25,000. Ascentis Independent Advisors acquired a new stake in IQVIA during the 1st quarter valued at $25,000. International Assets Investment Management LLC acquired a new stake in IQVIA during the 4th quarter valued at $27,000. Gilpin Wealth Management LLC bought a new position in IQVIA during the fourth quarter worth $27,000. Finally, CrossGen Wealth LLC acquired a new position in shares of IQVIA in the fourth quarter valued at $28,000. 89.62% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, insider Bhavik Patel sold 1,855 shares of the firm’s stock in a transaction on Friday, July 31st. The stock was sold at an average price of $235.27, for a total value of $436,425.85. Following the transaction, the insider owned 1,348 shares in the company, valued at approximately $317,143.96. This trade represents a 57.91% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Eric Sherbet sold 5,000 shares of the business’s stock in a transaction dated Wednesday, July 29th. The shares were sold at an average price of $249.16, for a total value of $1,245,800.00. Following the completion of the transaction, the insider directly owned 20,999 shares of the company’s stock, valued at approximately $5,232,110.84. This trade represents a 19.23% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 12,913 shares of company stock valued at $3,098,793 over the last 90 days. 1.70% of the stock is currently owned by insiders.

IQVIA Stock Performance

NYSE IQV opened at $237.97 on Friday. The firm has a 50-day moving average price of $200.92 and a two-hundred day moving average price of $186.95. IQVIA Holdings Inc. has a 12-month low of $154.50 and a 12-month high of $251.36. The company has a market capitalization of $39.17 billion, a P/E ratio of 29.53, a P/E/G ratio of 2.03 and a beta of 1.18. The company has a quick ratio of 0.71, a current ratio of 0.71 and a debt-to-equity ratio of 2.18.

IQVIA (NYSE:IQV) last announced its earnings results on Tuesday, July 28th. The medical research company reported $3.15 EPS for the quarter, topping the consensus estimate of $3.03 by $0.12. The company had revenue of $4.37 billion for the quarter, compared to analysts’ expectations of $4.30 billion. IQVIA had a net margin of 8.10% and a return on equity of 30.25%. The business’s revenue for the quarter was up 8.7% on a year-over-year basis. During the same period last year, the firm earned $2.81 earnings per share. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. Analysts anticipate that IQVIA Holdings Inc. will post 11.57 earnings per share for the current year.

IQVIA declared that its Board of Directors has approved a stock repurchase plan on Thursday, May 7th that permits the company to repurchase $2.00 billion in shares. This repurchase authorization permits the medical research company to purchase up to 6.8% of its stock through open market purchases. Stock repurchase plans are often a sign that the company’s management believes its shares are undervalued.

Analyst Ratings Changes

IQV has been the subject of a number of research reports. Robert W. Baird raised their target price on shares of IQVIA from $252.00 to $287.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 29th. Morgan Stanley reissued an “equal weight” rating and issued a $200.00 price target (down from $225.00) on shares of IQVIA in a report on Wednesday, June 17th. Royal Bank Of Canada raised their price objective on shares of IQVIA from $221.00 to $247.00 and gave the stock an “outperform” rating in a research report on Wednesday, July 29th. Stifel Nicolaus boosted their price objective on IQVIA from $220.00 to $276.00 and gave the stock a “buy” rating in a report on Wednesday, July 29th. Finally, Wall Street Zen upgraded IQVIA from a “hold” rating to a “buy” rating in a research note on Saturday, August 1st. One research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $241.88.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.